Entero Therapeutics (ENTO) 10-Q2020 Q1 Quarterly report

Filed: 15 May 20, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accelerated, accredited, accrual, acquisition, administered, adverse, age, allocated, allocation, alternative, Amgen, anniversary, applied, arm, assigned, bachelor, began, bifurcation, BioNJ, biopharmaceutical, brand, buy, career, category, Celgene, CFF, challenged, Charter, Clemson, CMC, Codification, Comprehensive, comprised, concurrently, constitute, criteria, crossed, crossover, cumulative, cutting, declined, degree, delay, delayed, delivered, delivery, Department, descriptive, Detachable, devoted, direct, directing, dissolution, divestiture, dividend, DSMB, economic, Edinboro, embedded, enacted, entertainment, entirety, entity, evidence, evolving, exact, exceed, exist, existing, exit, extent, failure, fall, fashion, flat, formula, frequently, global, gram, greater, Gregory, grow, growth, hierarchy, highly, host, hypothetical, identical, industry, inflammatory, input, instrument, integration, intellectual, introduced, IRB, judgment, largely, leadership, lesser, line, liquid, liquidation, loan, lower, lung, Merck, monotherapy, multiplied, national, negotiating, Network, nonrecurring, North, occurrence, open, Oppenheimer, oral, Otezla, pandemic, parallel, past, Paycheck, penalty, percent, Plant, policy, post, PPP, premium, Prepayment, profitability, Promissory, properly, prospectively, protection, qualitative, quality, quantitative, quoted, randomized, rapidly, ratably, ratio, reclassified, Recoverability, recruitment, Regular, reserved, resolved, restructure, returned, rolling, RRA, run, safe, Sandoz, SBA, scheduled, Schneiderman, scope, settle, settlement, single, sixty, Small, Spain, spending, Spinder, split, Squibb, steer, Step, supply, TDN, technical, technology, thereunder, timeline, Topic, travel, Turkey, unadjusted, unamortized, unchanged, uncontrolled, underwritten, undiscounted, unissued, University, Unobservable, unpaid, utilization, vi, Vice, volume

Removed: AAD, acceptable, accountable, accumulating, acid, advancing, Alexander, amoxicillin, antibiotic, assessing, break, charge, Christine, clavulanic, closer, collaboration, composed, degradation, detailed, diarrhea, Discounted, distinct, divided, dosing, enzymatic, escrow, examined, exercised, expensed, exploit, forgave, forward, function, Gottingen, government, granting, Helicobacter, hold, identification, induced, INRA, inverse, issuing, Lincoln, lump, minipig, mix, modification, modify, offer, offered, opportunity, origin, par, parenteral, Park, partner, presence, prevention, reducing, register, reimbursed, relation, relationship, released, reprice, repricing, resistant, shown, simplify, startup, strategic, sum, therapeutic, tract, transferred, TRANSFERT, unexercised, upper, Usage, world, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ENTO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AzurRx BioPharma, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Sapirstein, Chief Executive Officer of the Company, and Daniel Schneiderman, Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 15, 2020	/s/ James Sapirstein
	James Sapirstein President and Chief Executive Officer (Principal Executive Officer)


	/s/ Daniel Schneiderman Daniel Schneiderman Chief Financial Officer (Principal Financial and Accounting Officer)